Cardiovascular Diseases and COVID-19 Mortality and Intensive Care Unit Admission: A Systematic Review and Meta-analysis

Amir Shamshirian[1,2], Keyvan Heydari[2,3], Reza Alizadeh-Navaei[2], Mahmood Moosazadeh[4], Saeed Abrotan[5], Amirhossein Hessami[3*]

1- Department of Medical Laboratory Sciences, Student Research Committee, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran

2- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran

3- Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

4- Health Science Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran

5- Department of Cardiology, Babol University of Medical Sciences, Babol, Iran

***Corresponding author:**
Amirhossein Hessami
Student Research Committee,
School of Medicine,
Mazandaran University of Medical Sciences, Sari, Iran
Email: hessami.amirhossein@gmail.com

Word Count: 2017

Key Points:

Question: Are cardiovascular disease associated with mortality and Intensive Care Unit admission (ICU) of COVID-19 patients?

Findings: In this systematic review and meta-analysis, acute cardiac injury, hypertension, heart failure and overall cardiovascular diseases were significantly associated with mortality in COVID-19 patients. Arrhythmia, coronary heart disease, hypertension, acute cardiac injury and other cardiovascular disease were significantly associated with ICU admission of COVID-19 patients.

Meaning: Cardiovascular diseases have significant role in mortality and disease severity of COVID-19 patients. COVID-19 patients need to be carefully monitored for cardiovascular diseases and managed properly in case of acute cardiac conditions.

Abstract:

Importance: On 11th March, the World Health Organization declared a pandemic of COVID-19. There are over 1 million cases around the world with this disease and it continues to raise. Studies on COVID-19 patients have reported high rate of cardiovascular disease (CVD) among them and patients with CVD had higher mortality rate.

Objectives: Since there were controversies between different studies about CVD burden in COVID-19 patients, we aimed to study cardiovascular disease burden among COVID-19 patients using a systematic review and meta-analysis.

Data Sources: We have systematically searched databases including PubMed, Embase, Cochrane Library, Scopus, Web of Science as well as medRxiv pre-print database. Hand searched was also conducted in journal websites and Google Scholar.

Study Selection: Studies reported cardiovascular disease among hospitalized adult COVID-19 patients with mortality or ICU admission (primary outcomes) were included into meta-analysis. In addition, all of studies which reported any cardiovascular implication were included for descriptive meta-analysis. Cohort studies, case-control, cross-sectional, case-cohort and case series studies included into the study. Finally, 16 studies met the inclusion criteria for primary outcome and 59 studies for descriptive outcome.

Data Extraction and Synthesis: Two investigators have independently evaluated quality of publications and extracted data from included papers. In case of disagreement a supervisor solved the issue and made the final decision. Quality assessment of studies was done using Newcastle-Ottawa Scale tool. Heterogeneity was assessed using *I*-squared test and in case of high heterogeneity (>%50) random effect model was used.

Main Outcomes and Measures: Meta-analyses were carried out for Odds Ratio (OR) of mortality and Intensive Care Unit (ICU) admission for different CVDs and Standardized Mean Difference (SMD) was calculated for Cardiac Troponin I. We have also performed a descriptive meta-analysis on different CVDs.

Results: Sixteen papers including 3473 patients entered into meta-analysis for ICU admission and mortality outcome and fifty-nine papers including 9509 patients for descriptive outcomes. Results of meta-analysis indicated that acute cardiac injury, (OR: 15.94, 95% CI 2.31-110.14), hypertension (OR: 1.92, 95% CI 1.92-2.74), heart Failure (OR: 11.73, 95% CI 5.17-26.60), other cardiovascular disease (OR: 1.95, 95% CI 1.17-3.24) and overall CVDs (OR: 3.37, 95% CI 2.06-5.52) were significantly associated with mortality in COVID-19 patients. Arrhythmia (OR: 22.17, 95%CI 4.47-110.04), acute cardiac injury (OR: 19.83, 95%CI 7.85-50.13), coronary heart disease (OR: 4.19, 95%CI 1.27-13.80), cardiovascular disease (OR: 4.17, 95%CI 2.52-6.88) and hypertension (OR: 2.69, 95%CI 1.55-4.67) were also significantly associated with ICU admission in COVID-19 patients.

Conclusion: Our findings showed a high burden of CVDs among COVID-19 patients which was significantly associated with mortality and ICU admission. Proper management of CVD patients with COVID-19 and monitoring COVID-19 patients for acute cardiac conditions is highly recommended to prevent mortality and critical situations.

Keywords: COVID-19; Cardiovascular Disease; Meta-analysis

Introduction:

Coronaviruses are enveloped positive sense single stranded RNA viruses which cause respiratory infections in human and animals (1, 2). There were six coronaviruses known to cause infection in humans (3) including Sever Acute Respiratory Syndrome (SARS), China, 2002 (4) and Middle Eastern Respiratory Syndrome (MERS), Saudi Arabia, 2012 (5). The World Health Organization (WHO) reported cases of pneumonia with unknown source in Wuhan, China, December 2019 (6). Further investigations in samples of patients with respiratory infection, who were in contact with a seafood markets in Wuhan revealed a novel virus named 2019-nCoV (7). On 11th March, 2020 WHO declared the 2019-nCoV outbreak as a pandemic (8). According to Worldometer *info*, over 1 million confirmed cases and 61718 deaths due to COVID-19 have been reported throughout the world up to April 4th 2020 (9).

Acute infections are associated with increased risk of cardiovascular diseases (CVD) (10) including respiratory infections (11, 12). There is a mutual relationships between CVD and infections; while the viral respiratory infectious diseases like influenza might increase the risk of myocardial infarction and cardiovascular events (12), underlying CVD might increase the risk of mortality among patients with infection (13). Reports from COVID-19 disease including a large number of patients showed that fatality rate was 10.5% for CVD and 6.0% for hypertension among 72314 cases of COVID-19 (14). Studies indicated that there is an increased risk of mortality among hospitalized COVID-19 patients due to CVD (15-17).

Primary studies have been suggested high rate of mortality in COVID-19 patients with CVD, but there are still some controversies. Hence, we aimed to determine the mortality rate as well as Intensive Care Unit (ICU) admission associations in these patients using a systematic review and meta-analysis in order to overcome the controversies.

Methods:

Search Strategy:

In this study, Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines used for study design, search strategy, screening and reporting. The research question has been developed using PECO; "P" stands for Patients, "E" as Exposure, "C" as Comparison and "O" as Outcome. PECO components were as follows: "P"; hospitalized COVID-19 patients, "E"; CVDs, "C"; no CVD, "O"; ICU admission/mortality. A systematic search was done by A.H using all available MeSH terms and free keywords for "COVID-19", "Cardiovascular Disease" "Myocardial Infarction", "Heart Failure", "Hypertension", "Myocarditis", "Arrhythmia". Searched Databases included PubMed, Embase, Scopus, Web of Science, Cochrane Library, medRxiv pre-print database as well as Science Direct search engine. Hand search was done in publishers and journals databases including: Center for Disease Control and Prevention (CDC), The Journal of the American Medical Association (JAMA), The Lancet, The British Medical Journal (BMJ), Nature, Wiley, New England Journal of Medicine, Cambridge and Oxford. Our search included papers in English and Chinese and there were no time limitation publications. All original Cohort, Case Control, Cross-Sectional and Case-Series studies until 31th March 2020 were included.

Criteria for Study Selection

Two members of our team (A.H and A.S) selected the study independently and in case of disagreement R.A made the final decision. Studies met the following criteria included into systematic review: 1) Studies reporting characteristics of hospitalized COVID-19 patients; 2) Studies which reported any CVD in COVID-19 patients; 3) COVID-19 confirmed by Chest CT Scan, RT-PCR and hallmarks of the disease. Criteria for including studies into meta-analysis were: 1) Studies that reported CVD in COVID-19 patients admitted to ICU; 2) Studies reported the mortality rate of COVID-19 patients with underlying CVD; 3) Studies reported CVD among COVID-19 hospitalized patients. Studies were

excluded if they: 1) Reported outpatients or asymptomatic COVID-19 patients; 2) Not reported CVDs; 3) Review papers, case reports, *in vitro* studies and animal studies. Records have been entered into EndNote and duplications were removed.

Data Extraction

Two investigators (A.H and K.H) have independently evaluated quality of publications and extracted data from included papers. In case of disagreement a supervisor (R.A) solved the issue and made the final decision. Data extraction included first author name, publication year, country and following data extracted for each group (Total Sample, ICU, Non-ICU, Mortality, Survival): Sample size, mean ± standard deviation (SD) of age, number of females, number of males, heart failure, hypertension, other cardiovascular disease, acute cardiac injury, cardiomyopathy, myocardial damage, heart palpitation, coronary heart disease, arrhythmia, acute cardiac injury and cardiac troponin I mean ± SD. In cases that data was presented as median (interquartile range), a method by *Wan et al.* (18) was used to calculate mean ± SD.

Risk of Bias Assessment

Newcastle-Ottawa Scale tool was used for risk of bias assessment of studies included into meta-analysis (19). Risk of bias only assessed for studies entered into meta-analysis main outcomes (ICU and mortality) of the study (Figure 2,3).

Data Analysis

Odds Ratio (OR), and Standardized Mean Difference (SMD) with 95% confidence interval (CI) and pooled estimate prevalence rate were calculated using statistical analysis STATA v.11. In order to assess the heterogeneity, *I*-square (I^2) test was used. In case of high heterogeneity (more than 50%) random effect model was used for meta-analysis. Publication bias have been assessed using *Begg*'s test.

Results:

Study selection process

Our search through databases resulted in 329 papers. Eighty-seven duplicated papers have been excluded and after title and abstract screening, full texts of 81 papers were assessed for eligibility. Finally, 60 papers entered into qualitative synthesis, 16 papers (20-35) have entered into meta-analysis for primary outcomes and 59 papers (15, 20, 23-25, 29, 33, 34, 36-86) for descriptive outcomes. PRISMA flow diagram for the study selection process presented in Figure 1.

Study characteristics

Out of 16 papers included into meta-analysis for primary outcomes, four studies were case-control and four and eight of them were cross-sectional and cohort studies, respectively. The studies' sample size ranged from 41 to 1099 including 3473 participants. Characteristics of studies entered into meta-analysis for ICU and mortality outcome are presented in eTable 1 and studies entered into meta-analysis for descriptive outcomes in eTable 2. Fifty-nine papers entered into meta-analysis for descriptive outcomes including 16 cohorts, five case-control, 28 cross-sectional, nine case-series, one case-cohort. Studies sample size ranged from 2 to 1590 including 9509 patients.

Quality assessment

According to NOS tool for quality assessment, 16 studies earned the minimum eligibility score and entered into the meta-analysis for primary outcomes. Summary of risk of bias presented in Figure 2 and 3. *Begg*'s test showed that there was no considerable publication bias (*P*=0.7).

Mortality

The meta-analysis showed mortality rate of acute cardiac injury and coronary heart disease were 74% (95% CI 0.30-1.18) and 48% (95% CI 0.10-0.86) among COVID-19 patients. However, results indicated that mortality in COVID-19 patients with other cardiovascular disease was 55% (95% CI -0.22-1.31) but it was not statistically significant (Table 1).

Results of meta-analysis indicated that acute cardiac injury (OR: 15.94, 95% CI 2.31-110.14), Hypertension (OR: 1.92, 95% CI 1.92-2.74), Heart Failure (OR: 11.73, 95% CI 5.17-26.60), other cardiovascular disease (OR: 1.95, 95% CI 1.17-3.24) and overall CVDs (OR: 3.37, 95% CI 2.06-5.52) were significantly associated with mortality in COVID-19 patients. Odds of mortality of COVID-19 patients with heart failure was significantly higher than hypertension and other cardiovascular diseases (Table 2).

Intensive care unit admission

Carrying meta-analysis between groups of patients who admitted/do not admitted to the ICU showed the higher chance of ICU admission for males in compare to females, which was also more probable in older ages (SMD: 0.61, 95%CI 0.26-0.95). There were no statistically significant differences between two groups regarding levels of cardiac troponin I, however the effect size was considerable (SMD: 1.12, 95% CI -0.90-1.34) (Table 3).

The meta-analysis showed that the odds of patients with arrhythmia (OR: 22.17, 95%CI 4.47-110.04), acute cardiac injury (OR: 19.83, 95%CI 7.85-50.13), coronary heart disease (OR: 4.19, 95%CI 1.27-13.80), cardiovascular disease (OR: 4.17, 95%CI 2.52-6.88) and hypertension (OR: 2.69, 95%CI 1.55-4.67) were higher to being admitted to the ICU in compare to other group. Besides, the mortality rate was 47.86 times higher in ICU admitted COVID-19 patients than those patients who did not required the intensive care (Table 3).

Cardiovascular Complications

Fifty-nine studies have investigated for cardiovascular complications in the COVID-19 patients. Pooled prevalence of cardiovascular complications observed among patients with COVID-19 included hypertension (27%), cardiovascular and cerebrovascular disease (23%), heart failure (21%), acute cardiac injury (20%), coronary heart disease (17%), myocardial damage (16%), cardiovascular disease (12%), arrhythmia (11%), cardiomyopathy (12%) and heart palpitation (6%) (Table 4).

Discussion:

The results of this meta-analysis indicated cardiovascular implications including acute cardiac injury, arrhythmia, coronary heart disease, hypertension and other cardiovascular diseases were significantly associated with COVID-19 patient's admission to the ICU. Comparing pooled estimate of OR for CVDs in ICU admission did not show any significant differences between different cardiovascular implications. SMD for cardiac troponin *I* and OR for mortality was significantly higher among ICU patients than non-ICU. Odds for ICU admission was significantly higher in males than females. Investigating mortality outcome showed that mortality in patients with acute cardiac injury and coronary heart disease was significantly high. Comparing estimated prevalence of different cardiovascular complications including acute cardiac injury, arrythmia, cardiomyopathy, coronary heart disease, heart palpitation, hypertension, myocardial damage, heart failure and other cardiovascular diseases did not show any significant difference between them. Arrythmia, cardiomyopathy, heart palpitation and myocardial damage were not significantly prevalent among COVID-19 patients.

Cardiovascular complications have been previously reported in previous respiratory infections with similar etiology and their condition affects severity of the disease (16, 87), so that even hospitalization for pneumonia is associated with long-term and short-term risk of CVD (11). Viral infections cause imbalance between cardiac supply and demand and increase in systemic inflammation. Therefore

patients with pre-existing CVD have higher risks for acute cardiac conditions (88), infection and develop severe conditions during the infection (89). There are evidences that shows Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) binds to human angiotensin converting enzyme-2 (ACE2) to infect the cells (90) which being highly expressed in lungs and heart. Therefore, virus binding to ACE2 causes activation of renin-angiotensin system and its complications including hypertension, heart failure and atherosclerosis (89, 91, 92) as we resulted in our meta-analysis. These data could suggest a reason for high prevalence of hypertension in our pooled estimate.

This meta-analysis also indicated that mean age of COVID-19 patients admitted to ICU was significantly higher that non-ICU. An explanation to this condition by AlGhatrif *et al.* (93) suggested that elderly patients with hypertension are more likely to have downregulation of ACE2 expression, due to viral binding, and upregulated angiotensin *II* which exaggerates proinflammatory condition, predisposing them to severe conditions and mortality.

In our meta-analysis, acute cardiac injury was significantly higher in COVID-19 expired group, which was also in association with ICU admission. The pathophysiology of this condition is might be related to ACE2 and its related signaling pathways involved in heart function and other mechanisms including cytokines storm and hypoxemia caused by lung injuries (89). Cardiac troponin *I* can be an early biomarker for assessing risk of COVID-19 patients to perform an early intervention (15) as in our meta-analysis cardiac troponin *I* was significantly higher among ICU patients.

Limitation of this study was high heterogeneity of studies in population. Compounding effects of other co-morbidities in ICU admission and mortality was not being considered. It is possible that other co-morbidities related to respiratory system, renal system and gastrointestinal system affects patient's condition. We only included studies of hospitalized adult COVID-19 patients and asymptomatic and outpatients are excluded. Most of studies entered into meta-analysis have been conducted in China, therefore, population genetic variation is possible.

Conclusion:

In conclusion, CVD might have a significant role in disease severity and mortality of COVID-19 patients. Hypertension, acute cardiac injury and coronary heart diseases in COVID-19 patients needs to be carefully monitored and managed in case of acute conditions. Other cardiovascular implications including arrythmia and heart failure also needs to be considered since they can be fatal.

Conflicts of interests:

None of authors have declared any conflicts of interest.

Acknowledgments:

We acknowledge Student Research Committee of Mazandaran University of Medical Sciences for supporting this project (code number: 7396).

References:

1. Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660-94.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-74.
3. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology. 2016;24(6):490-502.
4. Peiris J, Guan Y, Yuen K. Severe acute respiratory syndrome. Nature medicine. 2004;10(12):S88-S97.
5. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine. 2012;367(19):1814-20.
6. Organization WH. Pneumonia of unknown cause–China. Emergencies preparedness, response, Disease outbreak news, World Health Organization (WHO). 2020.
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020.
8. Organization WH. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. Geneva, Switzerland. 2020.
9. Worldmeter.info. COVID-19 CORONAVIRUS PANDEMIC Dover, Delaware, U.S.A.2020 [Available from: https://www.worldometers.info/coronavirus/.
10. Cowan LT, Lutsey PL, Pankow JS, Matsushita K, Ishigami J, Lakshminarayan K. Inpatient and Outpatient Infection as a Trigger of Cardiovascular Disease: The ARIC Study. J Am Heart Assoc. 2018;7(22):e009683.
11. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang C-CH, et al. Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease. JAMA. 2015;313(3):264-74.
12. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007;28(10):1205-10.
13. Dhainaut J-F, Claessens Y-E, Janes J, Nelson DR. Underlying Disorders and Their Impact on the Host Response to Infection. Clinical Infectious Diseases. 2005;41(Supplement_7):S481-S9.
14. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020.
15. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020.
16. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020.
17. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020.
18. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology. 2014;14(1):135.
19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25(9):603-5.
20. Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, et al. Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. medRxiv. 2020.
21. Chen C, Yan J, Zhou N, Zhao J, Wang D. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua xin xue guan bing za zhi. 2020;48:E008-E.
22. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368.

23.   Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. medRxiv. 2020.

24.   Fu L, Fei J, Xiang H-X, Xiang Y, Tan Z-X, Li M-D, et al. Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study. medRxiv. 2020.

25.   Gu T, Chu Q, Yu Z, Fa B, Li A, Xu L, et al. History of Coronary Heart Disease Increases the Mortality Rate of Coronavirus Disease 2019 (COVID-19) Patients: A Nested Case-Control Study Based on Publicly Reported Confirmed Cases in Mainland China. medRxiv. 2020.

26.   Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020.

27.   He X, Lai J, Cheng J, Wang M, Liu Y, Xiao Z, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua xin xue Guan Bing za zhi. 2020;48:E011-E.

28.   Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.

29.   Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia. Investigative radiology. 2020.

30.   Peng Y, Meng K, Guan H, Leng L, Zhu R, Wang B, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua xin xue guan bing za zhi. 2020;48:E004.

31.   Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020.

32.   Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020.

33.   Zhang F, Yang D, Li J, Gao P, Chen T, Cheng Z, et al. Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study. medRxiv. 2020.

34.   Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China. medRxiv. 2020.

35.   Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.

36.   Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020.

37.   Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province, China. medRxiv. 2020.

38.   Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua xin xue guan bing za zhi. 2020;48:E008.

39.   Chen J, Fan H, Zhang L, Huang B, Zhu M, Zhou Y, et al. Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19. medRxiv. 2020.

40.   Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.

41.   Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020.

42.   He XW, Lai JS, Cheng J, Wang MW, Liu YJ, Xiao ZC, et al. [Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E011.

43.   Hsih W-H, Cheng M-Y, Ho M-W, Chou C-H, Lin P-C, Chi C-Y, et al. Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan. Journal of Microbiology, Immunology and Infection. 2020.

44.   Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.

45.	Hui H, Zhang Y, Yang X, Wang X, He B, Li L, et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv. 2020.

46.	Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese medical journal. 2020.

47.	Li J, Song H, Hu Z. Clinical features and outcomes of 2019 novel coronavirus-infected patients with cardiac injury. medRxiv. 2020.

48.	Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. International Journal of Infectious Diseases. 2020.

49.	Liu R, Ming X, Zhu H, Song L, Gao Z, Gao L, et al. Association of Cardiovascular Manifestations with In-hospital Outcomes in Patients with COVID-19: A Hospital Staff Data. medRxiv. 2020.

50.	Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clinical Infectious Diseases. 2020.

51.	Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua xin xue guan bing za zhi. 2020;48:E004.

52.	Qi D, Yan X, Tang X, Peng J, Yu Q, Feng L, et al. Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. 2020.

53.	Qian G-Q, Yang N-B, Ding F, Ma AHY, Wang Z-Y, Shen Y-F, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM: An International Journal of Medicine. 2020.

54.	Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020.

55.	Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases. 2020.

56.	Shi Q, Zhao K, Yu J, Feng J, Zhao K, Zhang X, et al. Clinical characteristics of 101 non-surviving hospitalized patients with COVID-19: A single center, retrospective study. medRxiv. 2020.

57.	Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. Journal of Medical Virology.n/a(n/a).

58.	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association. 2020.

59.	Wang K, Kang S, Tian R, Zhang X, Zhang X, Wang Y. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area. Clinical Radiology. 2020.

60.	Wang W, He J, Wu S. The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. Medrxiv. 2020.

61.	Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical Infectious Diseases. 2020.

62.	Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine. 2020.

63.	Wu C, Hu X, Song J, Du C, Xu J, Yang D, et al. Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). medRxiv. 2020.

64.	Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clinical Infectious Diseases. 2020.

65.	Xu H, Hou K, Xu H, Li Z, Chen H, Zhang N, et al. Acute Myocardial Injury of Patients with Coronavirus Disease 2019. medRxiv. 2020.

66.	Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. International Journal of Infectious Diseases. 2020.

67.   Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European Journal of Nuclear Medicine and Molecular Imaging. 2020.

68.   Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.

69.   Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020.

70.   Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv. 2020.

71.   Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy: European Journal of Allergy and Clinical Immunology. 2020.

72.   Zhao S, Ling K, Yan H, Zhong L, Peng X, Yao S, et al. Anesthetic Management of Patients With Suspected or Confirmed 2019 Novel Coronavirus Infection During Emergency Procedures. J Cardiothorac Vasc Anesth. 2020.

73.   Zhao Z, Xie J, Yin M, Yang Y, He H, Jin T, et al. Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, China. medRxiv. 2020.

74.   Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.

75.   Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of gastrointestinal symptoms on patients infected with COVID-19. Gastroenterology. 2020.

76.   Zhu Z, Tang J, Chai X, Fang Z, Liu Q, Hu X, et al. How to differentiate COVID-19 pneumonia from heart failure with computed tomography at initial medical contact during epidemic period. medRxiv. 2020.

77.   Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368:m1091.

78.   Fating Zhou XY, Xiaowei Tong, Rong Zhang. Clinical features and outcomes of 197 adult discharged patients with COIVD-19 in Yichang, Hubei. 2020.

79.   Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase, a Risk Factor of Severe COVID-19 Patients. medRxiv. 2020.

80.   Lijiao Zeng JL, Mingfeng Liao, Rui Hua, Pilai Huang, Mingxia Zhang, Youlong Zhang, Qinlang Shi, Zhaohua Xia, Xinzhong Ning, Dandan Liu, Jiu Mo, Ziyuan Zhou, Zigang Li, Yu Fu, Yuhui Liao, Jing Yuan, Lifei Wang, Qing He, Lei Liu, Kun Qiao. Risk assessment of progression to severe conditions for patients with COVID-19 pneumonia: a single-center retrospective study. medRxiv. 2020.

81.   Miao C, Zhuang J, Jin M, Xiong H, Huang P, Zhao Q, et al. A comparative multi-centre study on the clinical and imaging features of comfirmed and uncomfirmed patients with COVID-19. medRxiv. 2020.

82.   Nie S, Zhao X, Zhao K, Zhang Z, Zhang Z, Zhang Z. Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. medRxiv. 2020.

83.   Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020.

84.   Song FX, Shi NN, Shan F, Zhang ZY, Shen J, Lu HZ, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology. 2020;295(1):210-7.

85.   Xu S, Fu L, Fei J, Xiang H-X, Xiang Y, Tan Z-X, et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv. 2020.

86.   Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Comorbid Diabetes Mellitus was Associated with Poorer Prognosis in Patients with COVID-19: A Retrospective Cohort Study. medRxiv. 2020.

87.   Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases. 2016;49:129-33.

88.   Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020.

89.   Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020.

90.   Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020.

91.   Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020.

92.   South AM, Diz D, Chappell MC. COVID-19, ACE2 and the Cardiovascular Consequences. Am J Physiol Heart Circ Physiol. 2020.

93.   AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. JAMA Cardiology. 2020.

Table 1. Meta-analysis of pooled estimate prevalence of mortality among COVID-19 patients with CVDs

Complication	Number of Studies	Heterogeneity		Pooled Prevalence (95% CI)
		I-squared, %	Q (P-value)	
Acute Cardiac Injury	4	0.0	0.889	0.74 (0.30,1.18)
Coronary Heart Disease	5	0.0	0.811	0.48 (0.10, 0.86)
Other Cardiovascular Disease	2	0.0	0.517	0.55 (-0.22,1.31)

Table 2. Meta-analysis of Odd Ratio of CVDs for mortality outcome in COVID-19 patients

Complication	Number of Studies	Heterogeneity		Pooled OR (95% CI)
		I-Squared, %	Q (P-value)	
Acute Cardiac Injury	3	84.6	0.002	15.94 (2.31, 110.14)
Heart Failure	3	47.0	0.151	11.73 (5.17, 26.60)
Hypertension	7	34.1	0.168	1.92 (1.34, 2.74)
Other Cardiovascular Disease	4	23.5	0.270	1.95 (1.17, 3.24)
Overall	8	82.3	0.000	3.37 (2.06, 5.52)

Table 3. Meta-analysis of OR and SMD for ICU admission outcome among COVID-19 patients

| Complication | Number of Studies | Heterogeneity | | Pooled OR (CI 95%) |
		I-squared, %	Q (P-value)	/ SMD (CI 95%)
Acute Cardiac Injury	4	22.6	0.275	19.83 (7.85, 50.13)
Arrhythmia	2	68.7	0.074	22.17 (4.47, 110.04)
Coronary Heart Disease	3	69	0.040	4.19 (1.27, 13.80)
Hypertension	9	69.5	0.001	2.69 (1.55,4.67)
Mortality	5	43.6	0.131	47.86 (20.72,110.53)
Other Cardiovascular Diseases	6	0.0	0.750	4.17 (2.52,6.88)
Male to Female	6	0.0	0.819	1.61 (1.16, 2.23)
Age	7	74.9	0.001	0.61 (0.26, 0.95)
Cardiac Troponin I	4	0.0	0.680	1.12 (0.90, 1.34)

Table 4. Pooled prevalence for cardiovascular complications among COVID-19 patients

Complication	Number of studies	Heterogeneity		Prevalence (95% CI)
		I-Square (%)	Q (P-value)	
Coronary heart disease	16	0.0	0.990	0.17 (0.04,0.31)
Cardiovascular and cerebrovascular disease	7	0.0	0.949	0.23 (0.06,0.41)
Cardiovascular disease	28	0.0	1.000	0.12 (0.01,0.22)
Arrhythmia	8	0.0	1.000	0.11 (-0.12,0.33)
Acute cardiac injury	11	0.0	0.997	0.20 (0.07,0.33)
Cardiomyopathy	2	0.00	0.021	0.12 (-0.41,0.21)
Heart failure	8	0.0	0.977	0.21 (0.05,0.37)
Myocardial damage	3	93.35	0.00	18 (-0.11,0.47)
Hypertension	45	95.39	0.00	27 (0.22, 0.33)
Heart palpation	4	75.44	0.01	0.06 (-0.26, 0.46)